Restore Mind Medicine
The Irrefutable Need For Change
Poor Corporate
Governance and
Disconnected Pay for
Performance
Management Entrenchment
Board approved off-market golden
parachutes for all of management,
following FCM's calls for accountability.
Source: Company SEC Filings. See [5]
In 2021 and 2022, MindMed spent over $51
million on director and executive compensation.
MindMed is the only company in its peer group
to offer directors RSUS or DDSU rather than just
cash and options.
Board provided full bonuses to management for
normal course expectations, regulatory
compliance and even when MindMed failed to
meet its goals.
Board gave themselves a "one-time"
3-fold raise in 2022.
Inexperienced and
Unqualified Management
CEO Robert Barrow has NEVER brought
a drug to market nor run a pivotal trial.
He has just three years of psychedelic
experience.
CMO Danial Karlin's experience is in
bioinformatics and digital medicine, not
drug development.
13View entire presentation